Progyny (NASDAQ:PGNY) Stock: Insider Allison Swartz Sells 3,903 Shares

Key Points

• Progyny EVP Allison Swartz sold 3,903 shares at an average price of $26.10, totaling $101,868.30, under a pre-arranged Rule 10b5-1 trading plan. She retained 75,816 shares after the sale.
• PGNY traded near $25.52, with a market capitalization of approximately $1.96 billion. The company recently reported quarterly EPS of $0.55, exceeding the $0.33 analyst consensus, while revenue rose 5.3% year over year to $350.51 million.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $34.36 versus the current share price; institutional investors own approximately 94.93% of outstanding shares.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 3,903 shares of the stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the sale, the executive vice president directly owned 75,816 shares in the company, valued at approximately $1,978,797.60. This trade represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

PGNY stock traded up $0.08 during midday trading on Monday, reaching $25.52. The company had a trading volume of 1,011,013 shares, compared to its average volume of 1,407,611. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $33.06. The stock has a 50 day moving average price of $27.76 and a 200-day moving average price of $24.58. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 27.74, a price-to-earnings-growth ratio of 1.76 and a beta of 0.99.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. The firm had revenue of $350.51 million for the quarter, compared to the consensus estimate of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 1.25 earnings per share for the current year.

Institutional Trading of Progyny

A number of hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in shares of Progyny during the second quarter worth $29,000. Nykredit A S acquired a new stake in shares of Progyny during the 2nd quarter valued at $38,000. Hantz Financial Services Inc. grew its position in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company's stock worth $43,000 after acquiring an additional 742 shares during the last quarter. IFP Advisors Inc grew its position in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company's stock worth $57,000 after acquiring an additional 1,549 shares during the last quarter. Finally, Toth Financial Advisory Corp acquired a new position in Progyny in the 2nd quarter worth about $65,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners set a $38.00 price objective on shares of Progyny in a research report on Wednesday, July 22nd. Canaccord Genuity Group set a $35.00 target price on Progyny in a report on Friday, August 7th. BTIG Research lifted their price target on Progyny from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, July 24th. Jefferies Financial Group set a $33.00 price target on Progyny in a report on Tuesday, September 8th. Finally, Citizens Jmp upped their price objective on Progyny from $31.00 to $33.00 and gave the stock a "market outperform" rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Progyny currently has an average rating of "Moderate Buy" and a consensus price target of $34.36.

Progyny Company Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company's services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.